Chiang LingLi


Hong Kong + 852.3189.7338

Chiang Ling Li's practice has focused on China IP and pharmaceutical law since 1994. She has been in the forefront of the law, leading successful litigation involving patents, trade secrets, copyright, unfair competition, 3-D marks and well-known marks, as well as successfully pursuing criminal enforcement of IP infringement in China.

Chiang works closely with industry organizations lobbying for legal reforms, including those concerning patent linkage and data exclusivity, and has been appointed an arbitrator by CIETAC, HKIAC, ADNDRC, and the WIPO Arbitration and Mediation Center.

Chiang is author of China Executive Report: Intellectual Property, the China IP chapters of LexisNexis's Intellectual Property Rights, the "Anticounterfeiting and Enforcement" chapter in China's Participation in the WTO, and the China chapters in PLC Cross-border Life Sciences (2007-2012 editions), Trade Secrets Throughout the World Treatise, Patents Throughout the World, and Designs and Utility Models Throughout the World. She is also author of many articles on China IP and pharmaceutical law and practice.

Chiang was among the "A-List" of the top 100 lawyers for China (China Business Law Journal). She is also a PLC recommended lawyer in all three categories of life sciences: intellectual property, corporate and commercial (China), and corporate and commercial. Chiang also has been recognized by The International Who's Who of Life Sciences Lawyers, World Trademark Review (WTR 1000), Chambers Asia-Pacific and Chambers Global, The International Who's Who of Life Sciences Lawyers, The International Who's Who of Business Lawyers, IAM 1000 — The World's Leading Patent Professionals, WTR 1000 — The World's Leading Trademark Professionals, and IAM Licensing 250: The World's Leading Patent and Technology Licensing Practitioners.


  • STERIS acquires Cantel Medical for $3.6 billionJones Day advised STERIS plc in its acquisition of Cantel Medical Corp, a global provider of infection prevention products and services primarily to endoscopy and dental customers, for $3.6 billion.
  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day advised Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • Junshi Biosciences collaborates with Coherus Biosciences to co-develop anti-PD-1 antibody and grants options for anti-TIGIT and IL-2 cytokine moleculesJones Day represented Junshi Biosciences in its license out of technology and IP related to an anti-PD-1 antibody known as Toripalimab and options for two other molecules.
  • Junshi and Revitope team up for TEAC molecules through development, license, and equityJones Day represented Shanghai Junshi Biosciences Co., Ltd. in a research collaboration and license agreement with Revitope Oncology Inc. and its subsidiary to collaborate in the research and development of T-cell engaging cancer immunotherapies that utilize Junshi's antibody technology platform with Revitope's proprietary dual-antigen targeting technology platform.
  • Junshi and Lilly to develop and commercialize antibodies for prevention and treatment of COVID-19 coronavirusJones Day represented Shanghai Junshi Biosciences Co., Ltd. in its strategic collaboration and license agreement with Eli Lilly and Company for the development, manufacturing, and commercialization of two antibodies for the prevention and treatment of the COVID-19 SARS-CoV-2 novel coronavirus.
  • Power management company manufactures and distributes PPE during COVID-19 pandemicJones Day advised a power management company on regulatory and other issues related to manufacturing face masks for distribution to facilities and personnel in multiple jurisdictions including U.S., China, Taiwan, Japan, Australia/New Zealand, European Union, and Latin America.
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • Arsenal Capital Partners acquires HistoGeneX and Caprion BiosciencesJones Day advised Arsenal Capital Partners on major investments in HistoGeneX and Caprion Biosciences and the subsequent combination of the two businesses.
  • Incyte grants license to and collaborates with Zai Lab to develop and commercialize anti-PD1 pharmaceutical products in ChinaJones Day represented Incyte Corporation in its sublicense out to Zai Lab Limited of certain intellectual property rights to an anti-PD1 molecule licensed to Incyte from MacroGenics, Inc. globally in 2017 and which Incyte is actively developing in the U.S. and other jurisdictions outside of China.
  • Wipro acquires Splash CorporationJones Day advised Wipro Enterprises Private Ltd. (Wipro) in its acquisition of Splash Corporation, a leading personal care products player in the Philippines, from Ang Hortaleza Corporation.
  • Incyte enters strategic collaboration agreement with Innovent for three clinical pharmaceuticals in ChinaJones Day represented Incyte Pharmaceuticals in its strategic collaboration and license agreement with Innovent Biologics for the regulatory development and commercialization in China of three clinical stage pharmaceutical candidates, a FGFR1/2/3 inhibitor, a JAK1 inhibitor, and a PI3K delta inhibitor, for treatment of hematological and oncological diseases.
  • ANSYS acquires OPTISJones Day advised ANSYS, Inc., the global leader and innovator of engineering simulation software, on its acquisition of OPTIS, a premier provider of software for scientific simulation of light, human vision, and physics-based visualization.
  • AGIC Capital acquires Fotona from The Gores GroupJones Day advised Asia-Germany Industrial Promotion Limited ("AGIC Capital"), an Asian-European private equity investor focused on industrial technology companies in the European and North American mid-market, in connection with the acquisition and related financing of Fotona, a U.S. and Slovenia based developer of high-tech laser systems and components, primarily used in medicine, aesthetics, surgery, gynecology, and dentistry, from private equity firm, The Gores Group.
  • Cardinal Health acquires leading patient product portfolio from Medtronic for $6.1 billionJones Day advised Cardinal Health on the acquisition of Medtronic's Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion in cash.
  • Shore Capital Partners portfolio company acquires vertebroplasty family of products from Cook MedicalJones Day represented Shore Capital Partners in connection with the acquisition by portfolio company IZI Medical Products, LLC, a manufacturer of medical consumable accessories used in radiology, radiation therapy, and image guided surgery procedures, of the vertebroplasty family of products from Cook Medical, a family-owned medical device company.
  • Japanese company creates cross-border e-commerce platformJones Day advised Itochu Corporation and its affiliate in the establishment of a cross-border e-commerce platform with one of China's largest state-owned enterprises, CITIC Holdings Co. Ltd. and its affiliate.
  • U.S. biotechnology company reviews lab management consulting contract in ChinaJones Day advised a U.S. biotechnology company in relation to the lab management consulting contract reviews in China.
  • International medical device manufacturer protects against parallel imports in ChinaJones Day advised an international medical device manufacturer on strategizing its protection program for its medical devices in China against parallel imports from countries such as Australia, Singapore, and the United States.
  • International medical device company seeks trademark protection for its wound care products in ChinaJones Day advised an international medical device company on the protection of trademarks in China relating to technology in wound dressing products to stop bleeding, promote wound closure, and aid in wound healing.
  • Biopharmaceutical company seeks trademark protection for antibodies for pharmaceutical preparations in ChinaJones Day advised a biopharmaceutical company on the protection of trademark relating to the marker phosphatidylserine (PS) and antibodies for the treatment and diagnosis of cancer, infectious diseases, and diseases and disorders.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.